Evalon (vaccine against coccidiosis in chickens) – Summary of product characteristics - QI01AN01

Updated on site: 09-Feb-2018

Ravimi nimetus: Evalon
ATC: QI01AN01
Toimeaine: vaccine against coccidiosis in chickens
Tootja: Laboratorios Hipra, S.A.

1.NAME OF THE VETERINARY MEDICINAL PRODUCT

Evalon suspension and solvent for oral spray for chickens.

2.QUALITATIVE AND QUANTITATIVE COMPOSITION

Evalon:

Each dose (0.007 ml) of undiluted vaccine contains:

Active substances:

Eimeria acervulina, strain 003.....................................

332 – 450*

Eimeria brunetti, strain 034 .........................................

213 – 288*

Eimeria maxima, strain 013 .........................................

196 – 265*

Eimeria necatrix, strain 033.........................................

340 – 460*

Eimeria tenella, strain 004 ...........................................

276 – 374*

* Number of sporulated oocysts derived from precocious attenuated lines of coccidia, according to in vitro procedures of the manufacturer at the time of blending.

HIPRAMUNE T (solvent):

Adjuvant:

Montanide IMS

Excipients:

Brilliant Blue (E133)

Red AC (E129)

Vanillin

For the full list of excipients, see section 6.1.

3.PHARMACEUTICAL FORM

Suspension and solvent for oral spray.

Suspension: White turbid suspension.

Solvent: Dark brownish solution.

4.CLINICAL PARTICULARS

4.1Target species

Chickens.

4.2Indications for use, specifying the target species

For active immunisation of chicks from 1 day of age to reduce clinical signs (diarrhoea), intestinal lesions and oocysts output associated with coccidiosis caused by Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix and Eimeria tenella.

Onset of immunity: 3 weeks post-vaccination.

Duration of immunity: 60 weeks post-vaccination in an environment that permits oocysts recycling.

4.3Contraindications

None.

4.4Special warnings for each target species

The vaccine will not protect species other than chickens against coccidiosis and is only effective against the Eimeria species indicated.

It is normal to find vaccinal oocysts in the intestine or litter of vaccinated flocks. Generally the number is higher the first weeks post-vaccination and lower once the flock has achieved a proper protection.

4.5Special precautions for use

Special precautions for use in animals

Chickens must be strictly floor-reared in the first 3 weeks after vaccination.

Vaccinate healthy chickens only.

It is recommended that litter should be removed and facilities and material cleaned between production cycles to reduce field infections.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash and disinfect hands and equipment after use.

4.6Adverse reactions (frequency and seriousness)

None.

4.7Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during lay. Do not use in birds in lay and within 2 weeks before the onset of the laying period.

4.8Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

No anticoccidial substances or other agents having anticoccidial activity via feed or water should be used for at least 3 weeks following vaccination of the chickens. The correct replication of the vaccine oocysts and consequently, the development of a solid immunity could be hindered. Additionally, the enhancement of protection produced by oocyst re-infections would also be limited.

4.9Amounts to be administered and administration route

Oral use.

The method of administration is by coarse spray.

Vaccination schedule:

One dose of vaccine (0.007 ml) from 1 day of age.

Administration route:

The method of administration is by coarse spray by using a suitable device (volume delivered:

28 ml/100 chicks, droplet size: 200–250 µm and working pressure: 2 to 3 bars). Before starting the preparation, make certain to have a clean container available with sufficient capacity for preparing the diluted vaccine suspension. Dilute the vaccine with the corresponding volumes:

Doses

Water

Vaccine

Solvent

Total

1,000

223 ml

7 ml

50 ml

280 ml

5,000

1,115 ml

35 ml

250 ml

1,400 ml

10,000

2,230 ml

70 ml

500 ml

2,800 ml

Shake the solvent vial. Dilute the content of the vial with clean room temperature water into an appropriate container.

Shake the vaccine vial and dilute the content into the previous solution.

Fill the reservoir of the spraying device with all the vaccine suspension prepared.

Maintain the diluted vaccine suspension in continuous homogenisation by using a magnetic stirrer while the vaccine is being administered via coarse spray to the chicks.

To improve the uniformity of the vaccination maintain the chicks inside the transportation box for at least 1 hour in order to let them ingest all the vaccine droplets.

After this time, place the chicks carefully in the litter and continue with regular management practices.

The device should be cleaned after each use. See the manufacturer’s instructions to ensure proper disinfection and maintenance of the device.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Severe overdose (10-fold) may result in a temporary reduction in daily live weight gain within the first week without any consequences on the final performances.

4.11 Withdrawal period(s)

Zero days.

5.IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Immunological for Aves, live parasitic vaccines for domestic fowl. ATCvet code: QI01AN01.

To stimulate active immunity against coccidiosis caused by Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix and Eimeria tenella.

6.PHARMACEUTICAL PARTICULARS

6.1List of excipients

Evalon (vaccine)

Phosphate buffered solution (PBS):

-Potassium chloride

-Disodium phosphate dodecahydrate

-Potassium dihydrogen phosphate

- Sodium chloride

HIPRAMUNE T (solvent)

-Brilliant blue (E 133)

-Red AC (E 129)

-Vanillin

-Montanide IMS

6.2Major incompatibilities

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.

6.3Shelf life

Evalon (vaccine):

Shelf life of the veterinary medicinal product as packaged for sale: 10 months. Shelf life after first opening the immediate packaging: use immediately. Shelf life after dilution according to directions: 10 hours.

HIPRAMUNE T (solvent):

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

6.4.Special precautions for storage

Store and transport refrigerated (2 ºC–8 ºC).

Do not freeze.

6.5Nature and composition of immediate packaging

Evalon (vaccine)

10 ml, 50 ml or 100 ml type I colourless glass vials containing 7 ml, 35 ml or 70 ml of suspension (1,000, 5,000 and 10,000 doses) closed with type I polymeric elastomer closures and aluminium caps.

HIPRAMUNE T (solvent)

Polypropylene (PP) vials containing 50 ml, 250 ml and 500 ml of solvent closed with type I polymeric elastomer closures and aluminium caps.

Pack sizes

Cardboard box with one vial of 1,000 doses (7 ml) and one vial with 50 ml of solvent. Cardboard box with one vial of 5,000 doses (35 ml) and one vial with 250 ml of solvent. Cardboard box with one vial of 10,000 doses (70 ml) and one vial with 500 ml of solvent.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7.MARKETING AUTHORISATION HOLDER

LABORATORIOS HIPRA, S.A.

Avda. la Selva, 135

17170 Amer (Girona) SPAIN

Tel.: +34 972 430660 Fax: +34 972 430661 E-mail: hipra@hipra.com

8.MARKETING AUTHORISATION NUMBER(S)

EU/2/16/194/001–003

9.DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 18/04/2016

10 DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

Kommentaarid